冬虫夏草在肺部疾病中的潜在作用和研究进展  

Potential Role of Cordyceps sinensis in Lung Diseases and Advances in Research

作　　者：练东银 贺媛 徐丹 钱正明 李润峰[2] 杨子峰[2] LIAN Dongyin;HE Yuan;XU Dan;QIAN Zhengming;LI Runfeng;YANG Zifeng(Dongguan HEC Cordyceps R&D Co.,Ltd,Dongguan,Guangdong 523850,China;The First Affiliated Hospital of Guangzhou Medical University,Guangzhou Institute of Respiratory Health,State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou,Guangdong 510000,China)

机构地区：[1]东莞市东阳光冬虫夏草研发有限公司,广东东莞523850 [2]广州医科大学附属第一医院/广州呼吸健康研究院/呼吸疾病全国重点实验室/国家呼吸系统疾病临床医学研究中心,广东广州510000

出　　处：《今日药学》2024年第10期749-760,共12页Pharmacy Today

基　　金：广东省省级科技计划项目(2022A0505020031)。

摘　　要：冬虫夏草是中国的一种珍贵药材,具有补肾益肺,止血化痰的功效。冬虫夏草在肺部疾病(包括慢性阻塞性肺病、肺纤维化、肺癌及其相关并发症)中的潜在作用越来越受到关注。本文旨在探讨冬虫夏草在肺部疾病中的作用,主要关注其潜在的分子机制,这些机制可能作为诊断的标志物以及冬虫夏草治疗肺部疾病的潜在靶点,从而为其治疗提供新的策略。Cordyceps sinensis is a valuable Chinese medicinal herb known for its benefits in tonify the kidneys and lungs,stop bleeding and resolve phlegm.The potential role of Cordyceps sinensis in treating lung diseases,including chronic obstructive pulmonary disease,pulmonary fibrosis,lung cancer and its related complications,has garnered increasing attention.The aim of this article is to explore the role of Cordyceps sinensis in lung diseases,focusing mainly on the potential molecular mechanisms that may serve as diagnostic markers and therapeutic targets.,potentially offering new therapeutic strategies.

关 键 词：冬虫夏草 肺部疾病 分子机制 治疗作用 

分 类 号：R285[医药卫生—中药学]